Clinical and laboratory characterization of patients with localized scleroderma and response to UVA‐1 phototherapy: In vivo and in vitro skin models
Authors:
Open Access
- 3 April 2022
- journal article
- research article
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 38 (6) , 531-540
Abstract
Background/Purpose: Localized scleroderma (LS) is a rare disease leading to progressive hardening and induration of the skin and subcutaneous tissues. LS is responsive to UVA‐1 phototherapy, though its exact mechanism of action dermal fibrosis is yet to be fully elucidated. We aimed to investigate the molecular changes induced by UVA‐1 rays in human primary fibroblasts cultures.Methods: A total of 16 LS patients were treated with medium‐dose UVA‐1 phototherapy. At baseline, during and after therapy, Localized Scleroderma Assessment Tool, Dermatology Life Quality Index and lesions' staging and mapping were performed along with high‐frequency ultrasound (HFUS) examination for dermal thickness assessment. Gene expression analysis for 23 mRNA transcripts, in vitro UVA‐1 irradiation and viability tests were realized on lesional fibroblasts' primary cultures, before and 3 months after therapy.Results: The dermal thickness, the LoSCAT and the DLQI progressively decreased starting from the last phototherapy session up to the 6 and 9 month follow‐ups (−57% and −60%, respectively). Molecular gene analysis (rt‐PCR) revealed that UVA‐1 phototherapy exerts multiple effects: the activation of specific anti‐fibrotic pathways (e.g., overexpression of CTHRC1 and metalloproteases 1, 2, 7, 8, 9, 12, suppression of TIMP‐1), the downregulation of peculiar pro‐fibrotic pathways (e.g., downregulation of TGF‐ß, TGF‐ßrII, Grb2, SMAD 2/3, TNRSF12A, CTGF) through a significant overexpression of IL‐1ß; the stabilization of collagen synthesis acting on genes COL1A1, COL3A1, COL8A1, COL10A1, COL12A1.Conclusion: UVA‐1 phototherapy adds significant benefits in local tissue remodeling, rebalancing the alteration between pro‐fibrotic and anti‐fibrotic pathways; these changes can be well monitored by HFUS.Keywords
This publication has 47 references indexed in Scilit:
- UVA1 irradiation inhibits fibroblast proliferation and alleviates pathological changes of scleroderma in a mouse modelJournal of Biomedical Research, 2012
- Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoeaBritish Journal of Dermatology, 2010
- Development and initial validation of the Localized Scleroderma Skin Damage Index and Physician Global Assessment of disease Damage: a proof-of-concept studyRheumatology, 2009
- UVA1 phototherapy is effective in darker skin: a review of 101 patients of Fitzpatrick skin types I-VBritish Journal of Dermatology, 2008
- Effect of Increased Pigmentation on the Antifibrotic Response of Human Skin to UV-A1 PhototherapyArchives of Dermatology, 2008
- A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized sclerodermaJournal of the American Academy of Dermatology, 2006
- Low-dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosisJournal of the American Academy of Dermatology, 2004
- Suggested mechanisms of action of UVA phototherapy in morphea: a molecular studyPhotodermatology, Photoimmunology & Photomedicine, 2004
- Thirteen-megahertz ultrasound probe: its role in diagnosing localized sclerodermaBritish Journal of Dermatology, 2003
- Medium-dose UVA1 phototherapy in localized scleroderma and its effect in CD34-positive dendritic cellsJournal of the American Academy of Dermatology, 2001